Founded by a team led by the scientist who helped develop Bactroban, Alphyn Biologics is a clinical-stage dermatology company developing topical medicines for difficult skin diseases. Based in Annapolis and Cincinnati, the company’s botanical Zabalafin Platform uses multiple bioactive compounds to address several disease drivers at once, with lead programs targeting atopic dermatitis and molluscum contagiosum. Alphyn became operational in 2020 and has wholly owned subsidiaries in Australia and Austria.